Information Library

Results for: Lower portfolio & investment risks

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Partnering to Maximize Rewards in Pharmerging Markets

    White Paper — September 15, 2011
    In the past few years so-called “pharmerging” markets have been heralded as the hottest growth area for biopharmaceutical drugs. With large populations, growing disposable income and unmet medical needs, these markets have seen doubledigit growth rates in pharmaceutical spending.

  • Translational R&D Services Fact Sheet

    Brochure — May 26, 2011
    Quintiles’ Translational R&D Center of Excellence performs groundbreaking research and offers novel findings in oncology for biopharmaceutical companies.

  • Biomarkers in Alzheimers Disease

    Presentation — March 17, 2011
    The Quintiles Innovation Unit shares their knowledge on the use of biomarkers in compound development in clinical trials.

  • Quintiles Supports Samsung's Entry into BioPharma Market through Joint Venture

    Press Release — February 28, 2011 – The Samsung Group, South Korea’s largest industrial group, has entered into a strategic partnership with Quintiles, to support Samsung’s entry into the bio pharmaceuticals market.

  • Population PK/PD - Modeling and Simulation Optimization Tools

    Brochure — February 11, 2011
    Population pharmacokinetic/ pharmacodynamic (PK/PD) modeling and simulation, available from Quintiles, is now endorsed by the FDA as often being instrumental in drug approval and labeling.

  • The New Health Alliance

    White Paper — January 10, 2011
    Biopharmaceutical companies must explore alternative strategic alliances that meet the needs of the New Health and produce medicines that demonstrate value to the entire constellation of stakeholders.

  • Consulting – Breakthrough Thinking Built on Experience

    Brochure — November 23, 2010
    Consulting at Quintiles brings a critical element to engagements: fresh thinking built on a full lifecycle understanding of biopharma realities today.

  • Reinventing Safety

    Brochure — September 22, 2010
    When you integrate all your safety information, you can make better decisions, navigate regulatory hurdles and get to market faster.

  • Safety Strategy & Optimization

    Brochure — September 14, 2010
    Learn how to enable your safety group to become a value-added contributor throughout the product lifecycle.

  • Managing Pharmacovigilance as a Business

    White Paper — July 28, 2010
    The three steps required to develop a strategic approach to global capacity management.

Page 1 of 2 (19 results)

Subscribe to Email Based on Your Interests

Set preferences